Skip to main content

Table 1 Demographic and clinical characteristics of patients after first recurrence

From: Recurrent colorectal liver metastasis patients could benefit from repeat hepatic resection

Variable Local treatment Systemic chemotherapy P value
Resection RFA
Patients demographics n = 88 n = 85 n = 127  
Age (years) 55.6 ± 10.3 57.7 ± 9.3 56.1 ± 9.8 0.75
Sex ration (M:F) 57:31 59:26 80:47 0.83
Primary T
 T1-2 7 (8.0%) 7 (8.2%) 18 (14.2%) 0.23
 T3-4 81 (92.0%) 78 (91.8%) 109 (85.8%)  
Primary N
 N0 54 (61.4%) 66 (77.6%) 94 (74.0%) 0.82
 N1-2 34 (38.6%) 19 (22.4%) 33 (26.0%)  
Primary tumor location
 Colon 55 (62.5%) 52 (61.2%) 78 (31.4%) 0.95
 Rectum 33 (37.5%) 33 (38.8%) 49 (38.6%)  
 Right side 24 (27.3%) 17 (20.0%) 34 (26.8%) 0.75
 Left side 64 (72.7%) 68 (80.0%) 93 (73.2%)  
Timing of liver metastasis
 Synchronous 72 (81.8%) 78 (91.8%) 110 (86.6%) 0.53
 Metachronous 16 (18.2%) 7 (8.2%) 17 (13.4%)  
 Metastasis no 1 (1–7) 1 (1–3) 2 (1–5) 0.00
 Metastasis size(mm) 23.1 ± 15.8 15.6 ± 1.7 19.6 ± 10.2 0.00
Localization of liver metastases
 Unilobar 63 (71.6%) 70 (82.4%) 72 (56.7%) 0.00
 Bilobar 25 (28.4%) 15 (17.6%) 55 (43.3%)  
 CEA > 50 13 (14.8%) 4 (4.7%) 5 (3.9%) 0.00
 CA199 > 100 10 (11.4%) 6 (7.1%) 8 (6.3%) 0.18
Ras status
 Wild 62 (70.5%) 50 (58.8%) 77 (60.6%) 0.49
 Mutation 26 (29.5%) 35 (41.2%) 50 (39.4%)  
 Preoperative chemotherapy 49 (55.7%) 25 (29.4%) 127 (100%) NA
 Up-front local treatment 39 (44.3%) 60 (70.6%) 0  
No. of lines
 First line 25 (28.4%) 12 (14.1%) 70 (55.1%) NA
 Second line 24 (27.3%) 13 (15.3%) 47 (37.0%)  
 Others 0 0 10 (7.9%)  
Regimen
 Oxaliplatin 18 (20.5%) 9 (10.6%) 49 (38.6%) NA
 Irinotecan 31 (35.2%) 16 (18.8%) 70 (55.1%)  
 Others 0 0 8 (6.3%)  
 Biological agents 39 (44.3%) 20 (23.5%) 95 (74.8%) NA
 Bevacizumab 29 (33.0%) 18 (21.2%) 70 (55.1%)  
 Cetuximab 10 (11.3%) 2 (2.3%) 25 (19.7%)  
Response to chemotherapy
 Complete 0 0 0 NA
 Partial 4 (4.5%) 2 (2.4%) 21 (16.5%)  
 Stable disease 45 (51.1%) 23 (27.1%) 89 (70.1%)  
 Progressive disease 0 0 17 (13.4%)  
 Intraoperative RFA 8 (9.1%) NA NA  
 Operation time 204.4 ± 89.0 NA NA NA
 Blood lose 274.1 ± 77.1 NA NA NA
 RBC transfusion 2 NA NA NA
 R1 resection 6 NA NA NA
 Complication 4 NA NA NA
 Major 1 0 NA NA
 Adjuvant chemotherapy 66 (75%) 62 (73.0%) NA NA